TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Research analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of TScan Therapeutics in a report released on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.98) per share for the year, down from their previous forecast of ($0.97). Wedbush currently has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.96) EPS and FY2028 earnings at ($0.89) EPS.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.
Check Out Our Latest Analysis on TScan Therapeutics
TScan Therapeutics Stock Down 4.8 %
Shares of NASDAQ TCRX opened at $1.98 on Monday. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. The company’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $3.99.
Hedge Funds Weigh In On TScan Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC bought a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $61,000. Woodline Partners LP lifted its stake in TScan Therapeutics by 6.7% during the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after acquiring an additional 7,282 shares in the last quarter. Squarepoint Ops LLC purchased a new position in TScan Therapeutics during the 4th quarter worth $59,000. Tang Capital Management LLC bought a new stake in shares of TScan Therapeutics in the 4th quarter worth $358,000. Finally, Shay Capital LLC purchased a new stake in shares of TScan Therapeutics in the fourth quarter valued at about $65,000. Institutional investors and hedge funds own 82.83% of the company’s stock.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Featured Articles
- Five stocks we like better than TScan Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- 3 Warren Buffett Stocks to Buy Now
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.